Earlier this year Relmada Therapeutics, Inc. decided to amend its complaint against Laidlaw & Company. Relmada Therapeutics is a company centered on providing therapies to treat chronic pain. Relmada’s original lawsuit against Laidlaw was filed in Nevada District Court. The amended complaint includes allegations of breached fiduciary duties and disclosures of confidential information. The therapeutic company is also seeking monetary damages against Laidlaw. The Nevada District Court recently issued a temporary restraining order and injunction against Laidlaw and affiliated members of the company including James Ahern and Matthew Eitner. This injunction centered around Relmada’s allegations that Laidlaw disseminated false and misleading information. In addition to their amended complaint Relmada also issued a letter to all of its stockholders. The letter describes current actions that have been taken by Relmada to protect the interests of their stockholders. The letter also details how and why Relmada Therapeutics believes it has been harmed by Laidlaw & Company.
Laidlaw & Company previously provided Relmada with a host of services, including investment banking, agent placement support, and financial advising. Laidlaw previously operated under the name Sands Brothers International Ltd. The company has offices in both London and New York City. Matthew Eitner serves as Laidlaw’s Chief Executive Officer. James Ahern seres as Laidlaw’s Managing Partner and Head of Capital Markets. Eitner has experience with equity trading and investment strategy. Ahern has experience with investment banking and market share expansion.